OVID Earnings & Financial Statements
Ovid Therapeutics Inc.
$2.19
$0.00(0.00%)
42
Overall
60
Value
27
Tech
39
Quality
Market Cap
$427.70M
Volume
1.64M
52W Range
$1.18 - $3.11
Target Price
$5.74
OVID earnings and financial statements: Ovid Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
OVID Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $7.25M | $566.0K | $392.0K | $1.50M | $208.38M |
| Operating income | -$42.44M | -$61.88M | -$59.28M | -$55.55M | $124.21M |
| EBITDA | -$15.95M | -$24.72M | -$50.74M | -$54.17M | $124.45M |
| Net income | -$17.41M | -$26.43M | -$52.34M | -$54.17M | $122.83M |
| EPS (diluted) | $-0.23 | $-0.37 | $-0.74 | $-0.77 | $1.76 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $150.93M | $92.17M | $144.03M | $155.27M | $194.54M |
| Total liabilities | $20.27M | $23.94M | $56.23M | $22.99M | $14.80M |
| Shareholders’ equity | $130.66M | $68.23M | $87.80M | $132.27M | $179.75M |
| Cash and equivalents | $13.15M | $26.30M | $27.04M | $44.87M | $187.80M |
| Long-term debt | $11.99M | $13.42M | $14.76M | $16.00M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$38.30M | -$55.96M | -$45.78M | -$55.23M | $118.61M |
| Capital expenditure | - | -$161.0K | -$137.0K | -$1.42M | -$189.4K |
| Free cash flow | -$38.30M | -$56.12M | -$45.92M | -$56.65M | $118.42M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OVID | $2.19 | 0% | 1.64M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |